Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
University of Manchester · Salford Royal Hospital · +8 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
827
total citations
- FWCI
- 48.74
- Percentile
- 100%
- References
- 42
Citations per year
Authors
16- CGC.E.M. GriffithsCorresponding
University of Manchester, Salford Royal Hospital, Manchester Academic Health Science Centre
- KRKristian Reich
Dermatologikum Hamburg
- MLMark Lebwohl
Icahn School of Medicine at Mount Sinai
- PVPeter van de Kerkhof
Radboud University Nijmegen
- CPC. Paul
Université Toulouse III - Paul Sabatier
Topics & keywords
Topics
Keywords
- Ixekizumab
- Medicine
- Etanercept
- Placebo
- Psoriasis
- Psoriasis Area and Severity Index
- Internal medicine
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.